Postictal spectroscopy and imaging findings mimicking brain tumor recurrence
✍ Scribed by Elke Hattingen; Kea Franz; Ulrich Pilatus; Stefan Weidauer; Heiner Lanfermann
- Book ID
- 102374306
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 278 KB
- Volume
- 24
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
^1^H magnetic resonance spectroscopic imaging (MRSI) was performed on a patient with an admission diagnosis of recurrent astrocytoma. The patient had undergone surgical resection and radiation therapy for a left occipital astrocytoma WHO grade III 12 years previously, and presented with aphasia, right‐sided hemiparesis, and severe headache. Postcontrast T1‐weighted images showed cortical enhancement of the left parietotemporal lobe near the post‐resection cavity. MRSI revealed a marked increase of trimethylamines (TMA), elevated creatine/creatinephosphate (tCr), and reduced N‐acetyl‐aspartate (tNAA) in the same brain region. The spectroscopic data were consistent with tumor recurrence. However, the pattern of contrast enhancement on magnetic resonance imaging (MRI), evidence of an epileptic focus on electroencephalography (EEG), and spontaneous regression of the symptoms argued against tumor recurrence. In a 4‐week follow‐up, the contrast enhancement disappeared on MRI and the EEG abnormalities and neurological symptoms resolved. Follow‐up spectroscopic data showed a decrease in TMA compared to normal values. The tCr signal remained elevated but returned to normal values after 5 months. In conclusion, postictal neurological deficits with a temporary increase in TMA and tCr were diagnosed. This is the first report of seizure‐induced MRS abnormalities mimicking tumor recurrence. J. Magn. Reson. Imaging 2006. © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract To determine the potential value of multimodal MRI for the presurgical management of patients with brain tumors, we performed combined magnetic resonance imaging (MRI) and proton MR spectroscopy (MRS) in 164 patients who presented with tumors of various histological subtypes confirmed b